In a recent study, researchers at Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western), in collaboration with international colleagues, found that statins could be an effective therapeutic against metastatic small cell lung cancer (SCLC).
The study of 876 late-stage SCLC patients, published today in the peer-reviewed scientific journal PLOS ONE, showed that statins, a class of drugs primarily used to lower cholesterol in patients at risk for heart disease, appeared to provide an increase in overall survival for those cancer patients who received them.
“Small cell lung cancer is one of the most aggressive types of cancer, and yet in nearly three decades, no new classes of treatments have been adopted as new benchmarks for standard therapy,” said Dr. Glen Weiss, M.D., M.B.A., Director of Clinical Research and Medical Oncologist at CTCA® at Western in Goodyear, Ariz., and the study’s senior author. “Our study showed that statins appear to provide a statistically significant survival benefit among patients with metastatic SCLC.”
In collaboration with Dr. Weiss, Dr. Zoltan Lohinai, M.D., the study’s first author performed his analyses while based at CTCA under a grant from the Lung Cancer Research Scholarship of the Hungarian Society of Pulmonology 2015. Dr. Lohinai is a thoracic oncology fellow at the National Koranyi Institute of Pulmonology and a Ph.D. student at the Medical University of Budapest, Hungary. This international partnership expanded the data pool of patient information. With 51.6 cases per 100,000 people, Hungary has the world’s highest rate of lung cancer. That compares to 38.4 per 100,000 in the U.S., the world’s eighth highest rate of lung cancer.
Every year, lung cancer kills more than 158,000 Americans — more than breast, colon and prostate cancers combined. Nearly 1.8 million people worldwide are diagnosed with lung cancer each year.
Past drug-repositioning reviews, involving pre-clinical data and limited numbers of patients, appeared to have demonstrated anti-SCLC activity among some FDA-approved medications for treatment of non-malignant disorders.
“The aim of our study was to confirm whether the use of these non-cancer medications might be associated with a survival benefit for cancer patients,” Dr. Lohinai said.
This study published today examined late-stage SCLC patients who were prescribed statins, aspirin, clomipramine or serotonin reuptake inhibitors (antidepressants), and doxazosin or prazosin (medications for high blood pressure).
Significantly, their analyses appeared to show no statistical benefit for SCLC cancer patients taking any of those medications, except for statins.
“Our study evaluated the recent laboratory findings in a clinical setting. Among several studied drugs, statins were the only medications that appeared to increase the survival in patients suffering from this aggressive tumor,” Dr. Lohinai said. “We concluded that drug repositioning studies using only preclinical data or small numbers of patients should be treated with caution.”
Another finding of the this study was that radiotherapy appeared to be an independent predictor of survival.
“Our data demonstrated that radiotherapy appears to be an independent survival predictor in stage 4 SCLC, thereby confirming the results of other prospective and retrospective studies,” said Dr. Weiss, who leads the clinical research program at Western.
This study — From Bench to Bedside: Attempt to Validate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC) — was funded by a grant from Lung Cancer Research Scholarship of the Hungarian Society of Pulmonology 2015.
CTCA also acknowledges the support of Dr. Lohinai from the International Association for the Study of Lung Cancer International Mentorship Program 2015. This study was presented in part at the 16th IASLC World Conference on Lung Cancer, September 6-9, 2015, Denver, USA.